Published in Can J Cardiol on April 01, 2016
Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors. Breast Cancer Res Treat (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med (2013) 13.92
Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol (2005) 7.57
Guidelines for healthy weight. N Engl J Med (1999) 7.03
Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation (2007) 5.68
Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA (2001) 5.28
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 4.89
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ (2006) 4.79
An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv (2010) 4.73
Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol (2005) 4.21
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol (2009) 4.14
Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation (2015) 4.06
Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst (2012) 3.87
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation (2006) 3.71
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol (2003) 3.56
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst (2007) 3.55
Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol (2014) 3.48
Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation (2007) 3.20
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst (2008) 2.94
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst (2011) 2.66
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol (2006) 2.37
Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation (2014) 2.25
Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol (2012) 2.18
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res (2011) 2.13
Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. J Natl Cancer Inst (2015) 2.12
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A (2004) 2.07
Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol (2007) 1.97
Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation (2002) 1.84
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol (2015) 1.80
Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev (2009) 1.75
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol (2005) 1.68
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov (2011) 1.65
Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol (2014) 1.64
Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation (2009) 1.62
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem (2003) 1.60
Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev (2005) 1.56
Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation (2009) 1.55
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc (2008) 1.53
Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. Oncologist (2011) 1.52
Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology (2016) 1.52
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol (2002) 1.49
Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol (2003) 1.49
Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J (2009) 1.41
Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer (2010) 1.40
Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys (2006) 1.39
Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A (2001) 1.30
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation (2011) 1.30
Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr (2008) 1.24
The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res (2008) 1.23
Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. Acta Oncol (2015) 1.20
A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. Psychooncology (2002) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol (2012) 1.17
Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol (2012) 1.16
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist (2007) 1.15
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Temporal trends in breast cancer mortality by state and race. Cancer Causes Control (2008) 1.11
The association between resting heart rate, cardiovascular disease and mortality: evidence from 112,680 men and women in 12 cohorts. Eur J Prev Cardiol (2012) 1.10
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. Clin Cancer Res (2009) 1.04
Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension (2012) 1.04
Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. Oncologist (2007) 1.01
Cardiopulmonary responses and adherence to exercise in women newly diagnosed with breast cancer undergoing adjuvant therapy. Cancer Nurs (2006) 1.00
Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol (2012) 0.97
Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev (2007) 0.96
A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle (2015) 0.94
Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study. Breast Cancer Res Treat (2013) 0.94
Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study. Bone Marrow Transplant (2014) 0.93
High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. J Appl Physiol (1985) (2014) 0.92
Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol (2013) 0.91
Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol (2011) 0.90
Adjuvant aromatase inhibitors for breast cancer. Lancet (2005) 0.87
Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. Semin Oncol (2013) 0.85
Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology. Mayo Clin Proc (2015) 0.84
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat (2014) 0.84
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract (2014) 0.82
Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. JAMA Oncol (2015) 0.80
Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. Eur Urol (2013) 0.79
The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. Oncologist (2013) 0.79
Interval versus continuous aerobic exercise training in breast cancer survivors-a pilot RCT. Support Care Cancer (2015) 0.78
Influence of Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle Deoxygenation. PLoS One (2016) 0.77
Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. J Clin Oncol (2014) 0.76
Quantification of left ventricular performance in different heart failure phenotypes by comprehensive ergometry stress echocardiography. Int J Cardiol (2013) 0.75